ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

ANALYSIS OF PERSONALIZED TREATMENT IN PATIENTS WITH COLORECTAL LIVER METASTASES IN PAKISTAN

Dr Usman Tahir, Dr Nasir Azam, Dr Muhammad Abu Bakar

Colorectal cancer (CRC) is the second most common cancer type in the Western world, accounting for approximately 450,000 new cases in Europe each year. More than 200,000 patients die of the disease each year, which makes CRC still the second leading cause of cancer death in the Western world. Personalized medicine is defined by the US National Cancer Institute as ‘a form of medicine that uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat disease’. The basic aim of the study is to find the personalized treatment in patients with colorectal liver metastases in Pakistan. This cross-sectional study was conducted at Basic Health Unit 5 NP, Sadiqabad, Rahim Yar Khan during 2018. This study was done basically due to analysis of personalized treatment of colorectal liver metastases in Pakistan. We collected the data through pubmed and literature review analysis. One of the major advances in the treatment of CRC has been the development of targeted therapies. Amongst the most well-established of these are the monoclonal antibodies cetuximab and panitumumab, which target the EGFR. It is concluded that personalized medicine has made some major advances in CRC, with KRAS testing now part of routine clinical practice. However, KRAS has some limitations as a biomarker and despite extensive research into other biomarkers for antiangiogenic drugs, chemotherapy and other targeted agents, these are not yet established in clinical practice.

FULL TEXT